3Helix has developed a novel therapeutic platform leveraging bioACTIVE Collagen Hybridizing Peptides (CHPs) that selectively target damaged collagen in the extracellular matrix (ECM). Our technology delivers cell-binding sites in the required triple-helical confirmation to directly modulate cellular health in complex diseases, offering a unique approach beyond traditional cell-centric strategies. Validated in the cosmetics market (early revenues anticipated Q1 2026), our lead therapeutic is currently in preclinical trials with Phase I anticipated in Q4Y26.
Address
Salt Lake City
UT
United States
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}